Autoimmune Disease Therapeutics Market Size, Share, Growth Report 2030

Autoimmune Disease Therapeutics Market

Autoimmune Disease Therapeutics Market by Drug Class (Immunosuppressants, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, and Biologics), By Distribution Channel (Hospitals, Clinics, Drug Stores, and Independent Pharmacies), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 26-Jul-2022 Category: Healthcare Report Format : PDF Pages: 266 Report Code: ZMR-2140 Status : Published

The global autoimmune disease therapeutics market was worth around USD 54.8 billion in 2021 and is estimated to grow to about USD 113.48 billion by 2028, with a compound annual growth rate (CAGR) of approximately 12.9% over the forecast period.

Autoimmune Disease Therapeutics Market

Industry Perspective:

The global autoimmune disease therapeutics market was worth around USD 54.8 billion in 2021 and is estimated to grow to about USD 113.48 billion by 2028, with a compound annual growth rate (CAGR) of approximately 12.9% over the forecast period. The report analyzes the autoimmune disease therapeutics market’s drivers, restraints/challenges, and their effect on the demands during the projection period. In addition, the report explores emerging opportunities in the autoimmune disease therapeutics market.

Autoimmune Disease Therapeutics Market: Overview

Autoimmune illnesses are brought on by an autoimmune reaction that targets cells and destroys body tissue. Autoimmune disorders are nearly incurable and without a permanent cure. There are about 80 autoimmune disorders around the globe with unidentified causes. Over 300 million people worldwide have this condition, and between 70 and 80% of those sufferers are female. The two main drivers driving the market's expansion are the increased prevalence of autoimmune illnesses and the expanding understanding of these conditions. Over the projected period, the market development for autoimmune disease therapeutics is expected to be further bolstered by the expansion of autoimmune disease research and the rise in autoimmune disease therapeutic usage. Furthermore, technological developments in screening processes, widespread availability of therapeutics, and the significant presence of pipeline medications such as secukinumab, tocilizumab, certolizumab, tofacitinib, etanercept, and others are projected to have a positive impact on the market growth. The critical barriers to the worldwide autoimmune disease therapeutics market, however, include the lack of funding for developing nations, the high cost of treating the disease, the lack of availability of the medication in developing countries, and the development of substitute technologies. A stringent regulatory process and increasing treatment side effects are further factors that are expected to limit market expansion.

Global Autoimmune Disease Therapeutics Market

COVID-19 Impact:

The pandemic is influencing the therapeutic approach to a multifactorial disease such as rheumatoid arthritis (RA). Patients are at a higher infectious risk than the general population due to the overall immune system impairment associated with autoimmune diseases and the iatrogenic effect of immunosuppressive and corticosteroid drugs. However, growing awareness of the pathophysiology of the severe acute respiratory infectious disease leads to some anti-rheumatic drugs being considered as potential options for treating and managing COVID-19, resulting in the autoimmune disease therapeutics market growth.

Key Insights

  • The key factors driving the global market for autoimmune disease therapeutics include an increase in the prevalence of autoimmune disease, a surge in the use of therapeutics for the disorder, and an increase in R&D efforts to create the best possible treatments.
  • The main constraints for the global autoimmune disorder therapeutics market are insufficient funding in developing nations, high treatment costs, and treatment non-availability in developing countries.
  • By drug class, the anti-inflammatory drugs segment accounted market share of more than 30% in 2021.
  • The hospital segment is anticipated to grow at a CAGR of 5% from 2022 to 2028.
  • The Biologics segment will grow at a CAGR of 5.3% from 2022 to 2028.
  • In 2020, North America accounted largest revenue share of 42.4% 2021.
  • Europe is projected to grow at a CAGR of 6.5% from 2022 to 2028.

Autoimmune Disease Therapeutics Market: Growth Drivers

The growing prevalence of several autoimmune disorders drives the global market growth.

Factors contributing to the global autoimmune disease therapy market's growth include rising autoimmune disease prevalence, more patient awareness, and increased laboratory automation, which allows for the simultaneous diagnosis of several diagnostic tests, resulting in faster and more accurate findings thereby increasing patient awareness of such disorders fuels market expansion. Autoimmune illness targets healthy tissues, cells, and organs. It can affect any body area, weakening body function and threatening life. These illnesses sometimes need lifetime treatment to control symptoms because there is no known cure. Compared to men, women develop autoimmune diseases significantly more quickly. The condition is estimated to be one of the top ten causes of death among women under 65 and the second leading cause of chronic illness. Additionally, in the U.S., it is the leading cause of morbidity for women. There are currently over 80 clinically distinct types of autoimmune disorders. As a result, the autoimmune disease treatments market will expand throughout the forecast period.

Autoimmune Disease Therapeutics Market: Restraints

Lack of funding and high costs associated with treating the diseases may hamper the global market growth.

The key factors holding back the worldwide market for autoimmune disease therapies include insufficient funding in developing nations, the high cost of treating the condition, the lack of medication availability in developing countries, and the development of alternative technologies. The lack of understanding and awareness of autoimmune illnesses and their symptoms in poor & distant places would reduce their utilization in undeveloped and lower-income nations.

Autoimmune Disease Therapeutics Market: Opportunities

Improvements in healthcare infrastructure and technology bring up several growth opportunities.

Technology advancements such as the creation of novel biomarkers like Humira and Enbrel, compact diagnostic point-of-care devices, and growing preference for laboratory robotics are predicted to fuel growth throughout the forecast period. There is a surge in the sector due to constantly improving healthcare infrastructure and rising healthcare spending. Adopting sophisticated technology for improved treatment may pique more people’s attention in applying the medicine. The market value for treatments for autoimmune diseases might rise with higher adoption rates. Increased government spending on better medical facilities has several potential benefits for market expansion. New competitors may have chances in the worldwide market for treating autoimmune diseases due to the increased accessibility of biosimilar medications and more economical treatments.

Autoimmune Disease Therapeutics Market: Challenges

  • Quality and safety of autoimmune illness control therapy continue to be a global challenge: The quality and safety of autoimmune disorder control therapy may pose a challenge to the growth of the global autoimmune disease treatment market. The high cost of treatment is a significant disadvantage for the autoimmune disease diagnosis and treatment market share, and inadequate infrastructure in low-income geographic areas will slow illness syndrome treatment market growth.
  • Lack of awareness and skilled professionals for therapeutic procedures: Lack of knowledge and skilled workers may challenge market expansion. Lack of knowledge among the populace in any area can disregard the disease's subsequent, potentially lethal treatments. Some regions have poor healthcare facilities.

Autoimmune Disease Therapeutics Market: Segmentation

The global autoimmune disease therapeutics market is segregated based on drug class, distribution channel, and region.

By drug class, the market is divided into immunosuppressants, anti-inflammatory drugs, corticosteroids, nonsteroidal anti-inflammatory drugs, and biologics. Among these, the anti-inflammatory drugs segment dominates the market, accounting for more than 30% of global sales.

By distribution channel, the market is classified into hospitals, clinics, drug stores, and independent pharmacies. Over the forecast period, the hospital segment is expected to develop faster.

Recent Developments

  • January 2021 - Exagen Inc., an organization, committed to revolutionizing the care continuum for patients with autoimmune illnesses, stated that all AVISE test options (SLE Prognostic, Lupus, CTD, SLE Monitor, APS, MTX, Vasculitis AAV, and HCQ) were signed in-network service with Tufts Health Center, an esteemed academic medical center on a global scale.
  • August 2019 - The U.S. FDA authorized PerkinElmer, Inc.'s EUROIMMUN Anti-Tissue Transglutaminase ELISA to help doctors determine whether to confirm or rule out a diagnosis of celiac disease.

 

Report Scope:

Report Attribute Details
Base Year 2022
Historic Years 2018 - 2022
Forecast Years 2023 - 2030
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2023 to 2030
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Autoimmune Disease Therapeutics Market: Regional Landscape

Increasing government initiatives will help North America dominate the global market.

North America dominates the global autoimmune disease therapeutics market and accounted for more than 42.4% of the worldwide revenue in 2021. This is due to the rising prevalence of autoimmune diseases and the increased presence of government programs such as the Patient Protection Act and the Affordable Care Act. The market in this region is expanding due to rising healthcare spending, improved healthcare infrastructure, increased use of new technology, and the presence of significant vital players. The cost of treating autoimmune diseases is estimated to reach USD 100 billion annually in the United States, according to National Institute of Health estimates.

Over the forecast period, Europe is expected to be the fastest-growing regional market. The rising incidence of autoimmune diseases, expanding government efforts to upgrade the healthcare system, and increased adoption of cutting-edge technologies like portable diagnostic tools and novel biomarkers will all contribute to the expansion of the European market. High R&D activities, combined with the country's growing economic burden of autoimmune disorders, would impact regional development. Increased demand for more reliable diagnoses of systemic and localized diseases will also benefit the market.

Competitive Landscape

Some of the main competitors dominating the global autoimmune disease therapeutics market include - Chugai Pharmaceutical Co. Ltd, Amgen Inc, Eli Lilly and Company, Genentech Inc, Elan Corporation Plc, F. Hoffmann-La Roche AG, Squibb Company, Merck & Co. Inc, GlaxoSmithKline Plc, Bayer Schering Pharma AG, Biogen Idec Inc, Johnson & Johnson Inc, and Abbott Laboratories.

The global autoimmune disease therapeutics market is divided into the following segments:

By Drug Class

  • Immunosuppressants
  • Anti-Inflammatory Drugs
  • Corticosteroids
  • Nonsteroidal Anti-Inflammatory Drugs
  • Biologics

By Distribution Channel

  • Hospitals
  • Clinics
  • Drug Stores
  • Independent Pharmacies

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Factors contributing to the global autoimmune disease therapy market's growth include rising autoimmune disease prevalence, more patient awareness, and increased laboratory automation, which allows for the simultaneous diagnosis of several diagnostic tests, resulting in faster and more accurate results. The prevalence of these disorders is increasing, which boosts consumer awareness of the therapeutics market.

According to the Zion Market Research report, the global autoimmune disease therapeutics market was worth about 54.8 (USD billion) in 2021 and is predicted to grow to around 113.48 (USD billion) by 2028, with a compound annual growth rate (CAGR) of about 12.9%.

North America dominates the autoimmune disease therapeutics market and accounts for more than 42.4% of the global revenue. This is due to the rising prevalence of autoimmune illnesses and the increased prominence of government initiatives. Increasing healthcare expenditure, improved healthcare infrastructure, increased adoption of new technologies, and the presence of significant vital players are all contributing to the region's market growth.

Some of the main competitors dominating the global autoimmune disease therapeutics market include - Chugai Pharmaceutical Co. Ltd, Amgen Inc, Eli Lilly and Company, Genentech Inc, Elan Corporation Plc, F. Hoffmann-La Roche AG, Squibb Company, Merck & Co. Inc, GlaxoSmithKline Plc, Bayer Schering Pharma AG, Biogen Idec Inc, Johnson & Johnson Inc, and Abbott Laboratories.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed